Safety Profiles of Neurokinin-Targeted Therapies for VMS

Key Takeaways

• Elinzanetant showed significant efficacy in reducing VMS frequency and severity, with rapid symptom improvement compared to other treatments.
• The trials highlighted elinzanetant's positive impact on quality of life for women with severe VMS.
• Notable adverse events were observed, and the safety profile was compared with fezolinetant and traditional treatments, indicating its potential as an alternative.